|
Jul 30
|
VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives
|
|
Jun 25
|
VBI Vaccines Announces Results of Annual General Meeting
|
|
May 29
|
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
|
|
May 15
|
VBI Vaccines Reports First Quarter 2024 Financial Results
|
|
Apr 16
|
VBI Vaccines Reports Full Year 2023 Financial Results
|
|
Apr 11
|
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Apr 9
|
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Apr 3
|
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
|
|
Apr 2
|
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
|
|
Feb 14
|
Strategic Licensing Agreements: Brii Bio’s Expansion into Chronic Disease Treatments with VBI Vaccines
|
|
Feb 14
|
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
|